- Home
- CMPX vs DHF Comparison
CMPX vs DHF Comparison
Compare CMPX & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- DHF
- Stock Information
- Founded
- CMPX 2014
- DHF 1998
- Country
- CMPX United States
- DHF United States
- Employees
- CMPX N/A
- DHF N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- DHF Finance Companies
- Sector
- CMPX Health Care
- DHF Finance
- Exchange
- CMPX Nasdaq
- DHF Nasdaq
- Market Cap
- CMPX 291.8M
- DHF 172.4M
- IPO Year
- CMPX N/A
- DHF N/A
- Fundamental
- Price
- CMPX $2.60
- DHF $2.59
- Analyst Decision
- CMPX Strong Buy
- DHF
- Analyst Count
- CMPX 8
- DHF 0
- Target Price
- CMPX $13.13
- DHF N/A
- AVG Volume (30 Days)
- CMPX 955.2K
- DHF 451.1K
- Earning Date
- CMPX 08-11-2025
- DHF 01-01-0001
- Dividend Yield
- CMPX N/A
- DHF 7.65%
- EPS Growth
- CMPX N/A
- DHF N/A
- EPS
- CMPX N/A
- DHF N/A
- Revenue
- CMPX $850,000.00
- DHF N/A
- Revenue This Year
- CMPX N/A
- DHF N/A
- Revenue Next Year
- CMPX N/A
- DHF N/A
- P/E Ratio
- CMPX N/A
- DHF N/A
- Revenue Growth
- CMPX N/A
- DHF N/A
- 52 Week Low
- CMPX $0.77
- DHF $2.06
- 52 Week High
- CMPX $4.08
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- CMPX 62.59
- DHF 62.77
- Support Level
- CMPX $2.52
- DHF $2.50
- Resistance Level
- CMPX $2.71
- DHF $2.58
- Average True Range (ATR)
- CMPX 0.17
- DHF 0.02
- MACD
- CMPX 0.01
- DHF 0.00
- Stochastic Oscillator
- CMPX 72.88
- DHF 75.00
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.